Side-by-Side Comparison

Factor	Rybelsus	Victoza
Active Ingredient	Semaglutide (oral)	Liraglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA Approval Year	2019	2010
FDA Indication	T2D oral	T2D primary; CVD secondary
Formulation	Once-daily oral tablet	Once-daily subcutaneous injection
Dosing Frequency	Weekly	Daily
Starting Dose	0.25 mg	0.6 mg
Maximum Dose	2.4 mg	3.0 mg
Weight Loss (key trial)	~4.4% body weight reduction at 14 mg (PIONEER-1)	~3–4% body weight reduction (LEADER trial, T2D population)
Key Trial	PIONEER-6	LEADER
Cash Price (est. Q1 2026)	$900–$1,000/month	$700–$900/month
CVD Outcome Benefit	No / Not established	Yes

Cost estimates based on Q1 2026 data. Weight loss from named pivotal trials. Individual results vary. Verify current pricing with your pharmacy.

Which Is Right for You?

The "better" medication depends entirely on your individual medical history, insurance coverage, treatment goals, and tolerability. Here are key decision scenarios:

★ Primary goal is maximum weight loss

Based on clinical trial data, Rybelsus has demonstrated higher percentage weight loss in pivotal trials. Discuss whether the magnitude of difference is clinically meaningful for your situation with your prescriber.

★ You have type 2 diabetes as primary concern

Rybelsus and Victoza are FDA-approved for T2D management. Your prescriber will consider HbA1c targets, cardiovascular risk, renal function, and cost when choosing between them.

★ You have established cardiovascular disease

Victoza has demonstrated cardiovascular outcome benefits in clinical trials. For patients with high CV risk, Victoza may be preferred when clinically appropriate.

★ You want to avoid injections

Rybelsus (Rybelsus) is an oral tablet — the only non-injectable form of semaglutide. If injection avoidance is a priority, Rybelsus is worth discussing with your prescriber.

★ Cost is a primary factor

Cash prices differ significantly between medications. Rybelsus costs approximately $900–$1,000/month/month without insurance; Victoza costs approximately $700–$900/month/month. Both manufacturers offer savings programs for commercially insured patients. Use our Cost Estimator → to compare your specific situation.

Side Effect Comparison

Rybelsus Common Side Effects

•Nausea
•Vomiting
•Diarrhea
•Constipation
•Fatigue
•Injection Site Reaction
•Headache

Victoza Common Side Effects

•Nausea
•Diarrhea
•Constipation
•Vomiting
•Headache
•Injection Site Reaction
•Fatigue

Both medications share GI-related side effects as the most common adverse events. The profile is very similar because both belong to the GLP-1 receptor agonist class (or include GLP-1 agonism). Differences in tolerability are individual and cannot be predicted in advance.

Cost Comparison

Scenario	Rybelsus	Victoza
Cash pay / no insurance	$900–$1,000/month/mo	$700–$900/month/mo
Commercial insurance	$10/month with Novo Nordisk savings card for eligible commercially insured patients	$25–$50/month with commercial insurance and Novo Nordisk savings card
Mfr. savings program	Novo Nordisk Rybelsus Savings Offer	Novo Nordisk Victoza Savings Card

Estimated based on Q1 2026 data. Always verify with your pharmacy or plan.

💰 Estimate your personalized monthly cost →

Switching Guidance

If switching between Rybelsus and Victoza, consult your prescriber about the transition protocol. Key considerations include:

Whether to allow a washout period or transition directly
Starting dose for the new medication (may not match your current dose)
Insurance prior authorization requirements for the new medication
Monitoring frequency during transition

See our drug conversion calculator → for dose equivalency guidance.

Rybelsus vs Victoza: Which Is Better for Weight Loss in 2026?